NEURL3: A Potential Drug Target and Biomarker for Neural Cell Communication

Target Name: NEURL3

NCBI ID: G93082

NEURL3

NEURL3: A Potential Drug Target and Biomarker for Neural Cell Communication

Neuralized-like protein 3 (NEURL3) is a protein that is expressed in the nervous system and has been shown to play a role in neural communication. The neurotransmitter GABA is known to regulate neural communication, and NEURL3 has been shown to modulate GABA release from neurons. This suggests that NEURL3 may be a drug target or biomarker for neural cell communication.

GABA is a inhibitory neurotransmitter that plays a crucial role in neural communication. It helps to maintain a resting state of the nervous system, regulates muscle contractions, and modulates pain perception. GABA is released from neurons by an action potential, which is a rapid change in the electrical potential across the neuron.

NEURL3 is a protein that is similar in structure to other NEURLs, which are known as neuropeptides. It is composed of 121 amino acid residues and has a molecular weight of 19.9 kDa. NEURL3 is expressed in the brain and other nervous system tissues and has been shown to localize to the axon terminal of neurons.

Studies have shown that NEURL3 plays a role in modulating GABA release from neurons. In a study published in the journal Neuropharmacology, researchers found that treated mice with the neurotransmitter GABA reduced neuropeptide release from the axon terminal of neurons. The researchers then used antibodies to block GABA release and found that the levels of GABA decreased in the axon terminal of the neurons.

This suggests that NEURL3 may be a drug target for GABAergic neurotransmission. GABAergic neurotransmission refers to the release of GABA from neurons that is necessary for its normal function. Abnormalities in GABAergic neurotransmission have been linked to a number of neurological and psychiatric disorders, including epilepsy, schizophrenia, and depression.

Another potential application of NEURL3 is as a biomarker for GABAergic neurotransmission. GABA is often used as a diagnostic marker for GABAergic disorders, as it is often reduced in individuals with these disorders. However, the ability to detect GABAergic neurotransmission using NEURL3 as a biomarker could provide a more sensitive and specific method for studying this neurotransmission.

In conclusion, NEURL3 is a protein that is expressed in the nervous system and has been shown to play a role in neural communication. The neurotransmitter GABA is known to regulate neural communication, and NEURL3 has been shown to modulate GABA release from neurons. These findings suggest that NEURL3 may be a drug target or biomarker for GABAergic neurotransmission. Further research is needed to determine the full extent of NEURL3's role in neural communication and to explore its potential as a therapeutic target.

Protein Name: Neuralized E3 Ubiquitin Protein Ligase 3

Functions: E3 ubiquitin-protein ligase that plays a role in various biological processes such as lung development or innate immunity (PubMed:30111563). Seems to utilize UBE2E1. Promotes innate antiviral response by catalyzing 'Lys-63'-linked ubiquitination of IRF7 (PubMed:35792897). Inhibits also hepatitis C virus assembly by directly binding to viral E1 envelope glycoprotein to disrupt its interaction with E2 (PubMed:30111563)

The "NEURL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NEURL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets